EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Links between gut microbiome, metabolome, clinical variables and non‐alcoholic fatty liver disease severity in bariatric patients

Katherine J P Schwenger, Divya Sharma, Yasaman Ghorbani, Wei Xu, Wendy Lou, Elena M Comelli, Sandra E Fischer, Timothy D Jackson, Allan Okrainec, Johane P Allard iD

Liver International · 2024-05 · 44 (5) · 1176-1188

DOI: 10.1111/liv.15864 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver International, online erschienen am 14.02.2024. Verfasst von Katherine J P Schwenger und 9 weiteren Autor:innen. Beteiligte Einrichtung: Toronto General Hospital, University Health Network, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Gastrointestinal Microbiome, Bariatric Surgery, Obesity, Morbid. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIHR, Canadian Institutes of Health Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Bacterial species and microbial pathways along with metabolites and clinical parameters may interact to contribute to non‐alcoholic fatty liver disease (NAFLD) and disease severity. We used integrated machine learning models and a cross‐validation approach to assess this interaction in bariatric patients.

Methods

113 patients undergoing bariatric surgery had clinical and biochemical parameters, blood and stool metabolite measurements as well as faecal shotgun metagenome sequencing to profile the intestinal microbiome. Liver histology was classified as normal liver obese (NLO; n = 30), simple steatosis (SS; n = 41) or non‐alcoholic steatohepatitis (NASH; n = 42); fibrosis was graded F0 to F4.

Results

We found that those with NASH versus NLO had an increase in potentially harmful E. coli , a reduction of potentially beneficial Alistipes putredinis and an increase in ALT and AST. There was higher serum glucose, faecal 3‐(3‐hydroxyphenyl)‐3‐hydroxypropionic acid and faecal cholic acid and lower serum glycerophospholipids. In NAFLD, those with severe fibrosis (F3–F4) versus F0 had lower abundance of anti‐inflammatory species ( Eubacterium ventriosum , Alistipes finegoldii and Bacteroides dorei ) and higher AST, serum glucose, faecal acylcarnitines, serum isoleucine and homocysteine as well as lower serum glycerophospholipids. Pathways involved with amino acid biosynthesis and degradation were significantly more represented in those with NASH compared to NLO, with severe fibrosis having an overall stronger significant association with Superpathway of menaquinol‐10 biosynthesis and Peptidoglycan biosynthesis IV.

Conclusions

In bariatric patients, NASH and severe fibrosis were associated with specific bacterial species, metabolic pathways and metabolites that may contribute to NAFLD pathogenesis and disease severity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseGastrointestinal MicrobiomeBariatric SurgeryObesity, MorbidHumansEscherichia coliLiverFibrosisMetabolomeGlycerophospholipidsGlucose

Stichwörter der Autor:innen

fatty liverhepatic fibrosismetabolic pathwaysmetagenomemorbid obesity

Substanzen

GlycerophospholipidsGlucose

Autor:innen und Institutionen

  • Toronto General Hospital, University Health Network, Toronto, Ontario, Canada.
  • Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.
  • Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
  • Department of Nutritional Sciences, University of Toronto, Toronto, Ontario, Canada.
  • Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.

ORCID-Profile: Johane P Allard

Förderung

  • CIHR
  • Canadian Institutes of Health Research

Zitieren

APA

Schwenger, K. J. P., Sharma, D., Ghorbani, Y., Xu, W., Lou, W., Comelli, E. M., Fischer, S. E., Jackson, T. D., Okrainec, A., & Allard, J. P. (2024). Links between gut microbiome, metabolome, clinical variables and non‐alcoholic fatty liver disease severity in bariatric patients. Liver International, 44(5), 1176-1188. https://doi.org/10.1111/liv.15864

Vancouver

Schwenger KJP, Sharma D, Ghorbani Y, Xu W, Lou W, Comelli EM, et al. Links between gut microbiome, metabolome, clinical variables and non‐alcoholic fatty liver disease severity in bariatric patients. Liver International. 2024;44(5):1176-1188. doi:10.1111/liv.15864

BibTeX
@article{Schwenger2024,
  author = {Schwenger, Katherine J P and Sharma, Divya and Ghorbani, Yasaman and Xu, Wei and Lou, Wendy and Comelli, Elena M and Fischer, Sandra E and Jackson, Timothy D and Okrainec, Allan and Allard, Johane P},
  title = {Links between gut microbiome, metabolome, clinical variables and non‐alcoholic fatty liver disease severity in bariatric patients},
  journal = {Liver International},
  year = {2024},
  volume = {44},
  number = {5},
  pages = {1176--1188},
  doi = {10.1111/liv.15864}
}
Kostenlos starten →